Clinical correlations and long‐term follow‐up in 100 patients with sarcoglycanopathies. (21st November 2020)

• Record Type: Journal Article
• Authors: Guimarães‐Costa, R.; Fernández‐Eulate, G.; Wahbi, K.; Leturcq, F.; Malfatti, E.; Behin, A.; Leonard‐Louis, S.; Desguerre, I.; Barnerias, C.; Nougues, M. C.; Isapof, A.; Estournet‐Mathiaud, B.; Quijano‐Roy, S.; Fayssoil, A.; Orlikowski, D.; Fauroux, B.; Richard, I.; Semplicini, C.; Romero, N. B.; Querin, G.; Eymard, B.; Laforêt, P.; Stojkovic, T.
• Is Part Of: European journal of neurology. Volume 28:Number 2(2021)
• Page Start: 660
• Page End: 669
• Publication Date: 2020-11-21
• Subjects: genetic -- limb‐girdle muscular dystrophies -- neuromuscular diseases -- outcome measures -- sarcoglycan; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.14592
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Background and purpose: To describe a large series of patients with α, β, and γ sarcoglycanopathies (LGMD‐R3, R4, and R5) and study phenotypic correlations and disease progression. Methods: A multicentric retrospective study in four centers in the Paris area collecting neuromuscular, respiratory, cardiac, histologic, and genetic data. The primary outcome of progression was age of loss of ambulation (LoA); disease severity was established according to LoA before or after 18 years of age. Time‐to‐event analysis was performed. Results: One hundred patients (54 γ‐SG; 41 α‐SG; 5 β‐SG) from 80 families were included. The γ‐SG patients had earlier disease onset than α‐SG patients (5.5 vs. 8 years; p = 0.022) and β‐SG patients (24.4 years). Axial muscle weakness and joint contractures were frequent and exercise intolerance was observed. At mean follow‐up of 22.9 years, 65.3% of patients were wheelchair‐bound (66.7% α‐SG, 67.3% γ‐SG, 40% β‐SG). Dilated cardiomyopathy occurred in all sarcoglycanopathy subtypes, especially in γ‐SG patients ( p = 0.01). Thirty patients were ventilated and six died. Absent sarcoglycan protein expression on muscle biopsy and younger age at onset were associated with earlier time to LoA ( p = 0.021 and p = 0.002). Age at onset was an independent predictor of both severity and time to LoA ( p = 0.0004 and p = 0.009). The α‐SG patients showed genetic heterogeneity, whereas >90% of γ‐SG patients carried the homozygous c.525delT frameshift variant. Five new mutations were identified. Conclusions: This large multicentric series delineates the clinical spectrum of patients with sarcoglycanopathies. Age at disease onset is an independent predictor of severity of disease and LoA, and should be taken into account in future clinical trials. Abstract : This large multicentric Parisian series delineates the clinical spectrum of patients with sarcoglycanopathies. Age at disease onset and absence of sarcoglycan expression on muscle biopsy are predictors of severity of disease and loss of ambulation, and should be taken into account in future clinical trials.